Titre
Efficacy and safety of oral alitretinoin in severe oral lichen planus--results of a prospective pilot study.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Auteur(s)
Kunz, M.
Auteure/Auteur
Urosevic-Maiwald, M.
Auteure/Auteur
Goldinger, S.M.
Auteure/Auteur
Frauchiger, A.L.
Auteure/Auteur
Dreier, J.
Auteure/Auteur
Belloni, B.
Auteure/Auteur
Mangana, J.
Auteure/Auteur
Jenni, D.
Auteure/Auteur
Dippel, M.
Auteure/Auteur
Cozzio, A.
Auteure/Auteur
Guenova, E.
Auteure/Auteur
Kamarachev, J.
Auteure/Auteur
French, L.E.
Auteure/Auteur
Dummer, R.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1468-3083
Statut éditorial
Publié
Date de publication
2016-02
Volume
30
Numéro
2
Première page
293
Dernière page/numéro d’article
298
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
Patients with severe oral lichen planus refractory to standard topical treatment currently have limited options of therapy suitable for long-term use. Oral alitretinoin (9-cis retinoic acid) was never systematically investigated in clinical trials, although case reports suggest its possible efficacy.
To assess the efficacy and safety of oral alitretinoin taken at 30 mg once daily for up to 24 weeks in the treatment of severe oral lichen planus refractory to standard topical therapy.
We conducted a prospective open-label single arm pilot study to test the efficacy and safety of 30 mg oral alitretinoin once daily for up to 24 weeks in severe oral lichen planus. Ten patients were included in the study. Primary end point was reduction in signs and symptoms measured by the Escudier severity score. Secondary parameters included pain and quality of life scores. Safety parameters were assessed during a follow-up period of 5 weeks.
A substantial response at the end of treatment, i.e. >50% reduction in disease severity measured by the Escudier severity score, was apparent in 40% of patients. Therapy was well tolerated. Adverse events were mild and included headache, mucocutaneous dryness, musculoskeletal pain, increased thyroid-stimulating hormone and dyslipidaemia.
Alitretinoin given at 30 mg daily reduced disease severity of severe oral lichen planus in a substantial proportion of patients refractory to standard treatment, was well tolerated and may thus represent one therapeutic option for this special group of patients.
To assess the efficacy and safety of oral alitretinoin taken at 30 mg once daily for up to 24 weeks in the treatment of severe oral lichen planus refractory to standard topical therapy.
We conducted a prospective open-label single arm pilot study to test the efficacy and safety of 30 mg oral alitretinoin once daily for up to 24 weeks in severe oral lichen planus. Ten patients were included in the study. Primary end point was reduction in signs and symptoms measured by the Escudier severity score. Secondary parameters included pain and quality of life scores. Safety parameters were assessed during a follow-up period of 5 weeks.
A substantial response at the end of treatment, i.e. >50% reduction in disease severity measured by the Escudier severity score, was apparent in 40% of patients. Therapy was well tolerated. Adverse events were mild and included headache, mucocutaneous dryness, musculoskeletal pain, increased thyroid-stimulating hormone and dyslipidaemia.
Alitretinoin given at 30 mg daily reduced disease severity of severe oral lichen planus in a substantial proportion of patients refractory to standard treatment, was well tolerated and may thus represent one therapeutic option for this special group of patients.
Sujets
PID Serval
serval:BIB_3EFB14016A2D
PMID
URL éditeur
Date de création
2020-08-27T12:59:48.594Z
Date de création dans IRIS
2025-05-20T18:20:35Z